Abstract
P132 The randomized, phase 3 MK-5684-004 study of CYP11A1 inhibitor opevesostat versus Next-generation Hormonal Agent (NHA) switch in patients with metastatic Castration- Resistant Prostate Cancer (mCRPC) After 1 Prior NHA
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
